Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Where Will Eli Lilly Be in 1 Year?

TheMotleyFool

0 0

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating type 2 diabetes and Zepbound for chronic weight management. Due to this growth story, the stock has ripped off over 180% in gains over the past three years.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024.

The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year. Where might Eli Lilly be in a year, and should investors buy the stock now?

Source Fool.com

Like: 0

LLY

Share